No­vo Seeds launch­es a new neu­ro biotech as Alzheimer's R&D booms

No­vo Hold­ings’ seed cap­i­tal arm No­vo Seeds is once again launch­ing a new biotech, and this time it comes from the com­bi­na­tion of two Eu­ro­pean star­tups.

The new­co will take the ef­forts of Den­mark’s Mu­na Ther­a­peu­tics and Bel­gium’s K5 Ther­a­peu­tics and fold them in­to one com­pa­ny, which will re­tain the Mu­na name. No­vo Seeds is fronting the Se­ries A with $73 mil­lion as the biotech looks to treat neu­rode­gen­er­a­tive dis­eases like Alzheimer’s, Parkin­son’s and ALS.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.